COPD News
-
RESTECH and VIVISOL together to bring innovative monitoring at home of COPD patients
RESTECH srl and VIVISOL has established a long-term commercial partnership to commercialize the RESMON PRO DIARY and its innovative algorithm for the detection of the risk of exacerbation in COPD patients. Thanks to this collaboration RESTECH will be able to consolidate its operative know-how and bring the latest innovations in home monitoring directly in the homes of COPD patients of the main ...
By Restech Srl
-
Showcase
AioCare system could be successfully applied in primary healthcare Centers.
The role of spirometry in diagnosing and monitoring chronic obstructive airway diseases is crucial. According to WHO, the demonstration of irreversible airway obstruction is essential for diagnosing chronic obstructive pulmonary disease (COPD), which is the third leading cause of death worldwide. It is estimated that up to 67–81% of patients with COPD remain undiagnosed. Mobile phone-linked ...
By AioCare
-
Dynamic Air Quality Solutions announces Partnership with COPD Foundation
Dynamic Air Quality Solutions, a manufacturer and distributor of high-performance indoor air quality products, announced today that it is partnering with the COPD Foundation to help increase awareness about Chronic Obstructive Pulmonary Disease (COPD) and to improve the lives of an estimated 30 million people living with COPD in North America. COPD is the 3rd leading cause of death in North ...
-
Circassia Announces FDA Approval of Tudorza Supplemental New Drug Application
Oxford, UK – 29 March 2019: Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR), a specialty pharmaceutical company focused on respiratory disease, today announces the US Food and Drug Administration (FDA) has approved Tudorza®’s supplemental New Drug Application (sNDA) for the inclusion of unique new clinical data in the product’s ...
-
Circassia Announces FDA Approval of Duaklir for Maintenance Treatment of Chronic Obstructive Pulmonary Disease
Oxford, UK – 1 April 2019: Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR), a specialty pharmaceutical company focused on respiratory disease, today announces the US Food and Drug Administration (FDA) has approved Duaklir® for the maintenance treatment of chronic obstructive pulmonary disease (COPD). Duaklir® is a fixed-dose combination ...
-
Circassia Announces FDA Approval of Duaklir for Maintenance Treatment of Chronic Obstructive Pulmonary Disease
Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR), a specialty pharmaceutical company focused on respiratory disease, today announces the US Food and Drug Administration (FDA) has approved Duaklir® for the maintenance treatment of chronic obstructive pulmonary disease (COPD). Duaklir® is a fixed-dose combination of the long-acting muscarinic ...
-
Circassia Announces FDA Approval of Tudorza Supplemental New Drug Application
Data showing reduction in COPD exacerbations and no increase in major cardiovascular events vs placebo added to label – – Tudorza® is the only product in its class with these data in the label Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR), a specialty pharmaceutical company focused on respiratory disease, today announces the US ...
-
Circassia Announces Duaklir US Launch at American College of Chest Physicians’ CHEST Annual Meeting 2019
Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR), a specialty pharmaceutical company focused on respiratory disease, today announces the US launch of Duaklir® for the maintenance treatment of chronic obstructive pulmonary disease (COPD) at the American College of Chest Physicians’ CHEST Annual Meeting 2019, which is currently ongoing in New ...
-
Circassia Announces Publication of Tudorza Phase IV ASCENT Study in the Journal of the American Medical Association
Oxford, UK – 8 May 2019: Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR), a specialty pharmaceutical company focused on respiratory disease, today announces the full publication of the Tudorza® phase IV ASCENT study in the prestigious Journal of the American Medical Association*. The ASCENT study was conducted in patients with ...
-
Circassia Announces Publication of Tudorza Phase IV ASCENT Study in the Journal of the American Medical Association
Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR), a specialty pharmaceutical company focused on respiratory disease, today announces the full publication of the Tudorza® phase IV ASCENT study in the prestigious Journal of the American Medical Association*. The ASCENT study was conducted in patients with moderate-to-very severe chronic obstructive ...
-
Circassia Announces Duaklir New Drug Application (NDA) and Tudorza Supplemental NDA Accepted for Review by FDA
Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR), a specialty pharmaceutical company focused on respiratory disease, today announces that the United States Food and Drug Administration (FDA) has confirmed it has completed its validation for completeness, and accepted for filing and review, the previously submitted Duaklir® New Drug Application ...
-
CHROMED trial completed successfully
Restech, in its role of technical manager and together with all the partner of the project, successfully concluded the CHROMED trial. With 312 patients enrolled and studied for 9 months by 6 clinical centers in 5 EU Countries, CHROMED has been the largest international multi-center randomized control trial evaluating the effectiveness of an integrated telecare approach for COPD patients based on ...
By Restech Srl
-
Simeox device is now available in Canada!
We are happy to announce that the #simeox device is now commercially available in Canada. Proud to partner with Novus Medical to help respiratory clinicians improve the life of their patients through access to Simeox. The Simeox device is an efficient and comfortable therapy for distal mucus clearance – for patients suffering from chronic lung conditions associated with chest congestion, ...
By PhysioAssist
-
Circassia Announces Submission of Duaklir New Drug Application and Tudorza Supplemental New Drug Application in the United States
Duaklir® NDA for treatment of chronic obstructive pulmonary disease (COPD) Tudorza® sNDA for inclusion of COPD exacerbation reduction and cardiovascular safety data in label Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR), a specialty pharmaceutical company focused on respiratory disease, today announces the submission of a New Drug ...
-
Restech announces the clinical validation of the Resmon Pro Diary to remotely monitor COPD at home.
The CHROMED trial, one of the largest clinical trial using FOT to monitor remotely COPD patients and prevent exacerbation has now been published on the American Journal of Respiratory and Critical care medicine! Using the RESMON PRO DIARY (the home version of the well proven, hospital, clinical unit, the RESMON PRO FULL), 312 patients from 5 different European countries have been successfully ...
By Restech Srl
-
National COPD Awareness Month and Identifying Airborne Exposure Risks in Puerto Rico
November is recognized as National COPD Awareness Month. The NIH’s National Heart, Lung, and Blood Institute states that it is a distinct time for the COPD community to come together with one voice to focus on increasing awareness of the disease. Across the nation, organizations are conducting outreach and holding events to bring greater visibility to COPD and to encourage people to ...
-
Circassia to Exercise Option for Full US Commercial Rights to COPD Treatment Tudorza from AstraZeneca
Oxford, UK – 11 December 2018: Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR), a specialty pharmaceutical company focused on respiratory disease, today announces it has issued a notice of option exercise to AstraZeneca to acquire the full US commercial rights to Tudorza® (aclidinium). Circassia currently promotes the COPD treatment in the ...
-
National COPD Awareness Month Discussed in New Online Video
Today the IAQ Video Network and Cochrane & Associates announced the release of their latest educational video. Their newest production discusses National COPD Awareness Month, which takes place during the month of November. “Chronic Obstructive Pulmonary Disease (COPD) is a serious lung disease that impacts millions of Americans, and hundreds of millions worldwide, making it hard to ...
-
Circassia Announces Positive Data Presented at 2018 American Thoracic Society Conference from Tudorza Phase IV and Duaklir Phase III Studies
Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR), a specialty pharmaceutical company focused on respiratory disease, today announces the presentation of positive clinical data from the Tudorza® Pressair® phase IV ASCENT study and Duaklir® Pressair® phase III AMPLIFY study at the American Thoracic Society (ATS) 2018 International ...
-
Lupin Receives Approval from U.S. FDA for Arformoterol Tartrate Inhalation Solution15 mcg (base)/2 ml
Global pharma major Lupin Limited (Lupin) today announced that it has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), Arformoterol Tartrate Inhalation Solution 15 mcg (base)/2 ml, Unit-dose Vialsto market a generic equivalent of Brovana®Inhalation Solution, 15 mcg/2 ml of Sunovion Pharmaceuticals Inc. (Sunovion). ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you